|
Autistic Disorder
|
0.330 |
Therapeutic
|
disease |
CTD_human |
After administration of secretin, the Autism Diagnostic Interview-Revised (ADI-R) score improved in 7 of the 12 children.
|
16168596 |
2006 |
|
Autistic Disorder
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
We did not find evidence of a relationship between human secretin gene mutation and autism.
|
16225821 |
2005 |
|
Autistic Disorder
|
0.330 |
Therapeutic
|
disease |
CTD_human |
These findings suggest that secretin promotes the metabolism of serotonin and dopamine in the central nervous system, which may contribute to improvement in clinical symptoms of autism.
|
15272612 |
2004 |
|
Autistic Disorder
|
0.330 |
Therapeutic
|
disease |
CTD_human |
Since autism is hypothesized to be a hypoglutamatergic disorder we investigated the in vivo effects of secretin on extracellular amino acids in the rat brain.
|
15206007 |
2004 |
|
Autistic Disorder
|
0.330 |
Therapeutic
|
disease |
CTD_human |
Recent observations that the deficits in social reciprocity skills seen in young (3-4-year-old) autistic children are improved after secretin infusions suggest an additional influence on neuronal activity.We show here that i.v. administration of secretin in rats induces Fos protein expression in the neurons of the central amygdala as well as the area postrema, bed nucleus of the stria terminalis, external lateral parabrachial nucleus and supraoptic nucleus.
|
12732234 |
2003 |
|
Autistic Disorder
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
The human secretin gene: fine structure in 11p15.5 and sequence variation in patients with autism.
|
12160732 |
2002 |
|
Autistic Disorder
|
0.330 |
GeneticVariation
|
disease |
LHGDN |
While the secretin gene (SCT) was not found to be mutated in the majority of autistic patients, rare heterozygous sequence variants were identified in three patients.
|
12160732 |
2002 |
|
Autistic Disorder
|
0.330 |
Biomarker
|
disease |
BEFREE |
The study of the transcriptional control of human secretin and its receptor should shed light on the pathological developments of pancreatic cancer and autism in the future.
|
10437774 |
1999 |
|
Polycystic Ovary Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.
|
21411543 |
2011 |
|
Sclerocystic Ovaries
|
0.300 |
Biomarker
|
disease |
CTD_human |
Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.
|
21411543 |
2011 |
|
Choledochal Cyst
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
|
18988797 |
2008 |
|
Choledochal Cyst, Type I
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
|
18988797 |
2008 |
|
Choledochal Cyst, Type II
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
|
18988797 |
2008 |
|
Choledochal Cyst, Type III
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
|
18988797 |
2008 |
|
Choledochal Cyst, Type IV
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
|
18988797 |
2008 |
|
Choledochal Cyst, Type V
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
|
18988797 |
2008 |
|
Tachycardia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Secretin increased heart rate by 14 beats/min (20% above base-line) and this also was not altered by propranolol pretreatment.
|
2103752 |
1990 |
|
Tachyarrhythmia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Effect of propranolol on secretin-induced gastrin release and secretin-induced tachycardia in patients with the Zollinger-Ellison syndrome.
|
2103752 |
1990 |
|
Graft-vs-Host Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, the 7 cases of IA after allo- SCT occurred only in patients treated with corticosteroids for graft-versus-host disease (GVHD).
|
28689016 |
2019 |
|
Graft-vs-Host Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Grade 2-4 acute graft-versus-host disease (GVHD) at 100-day post-DLI was higher in HID-SCT group than that in MSD-SCT group (59.5% vs. 30.8%, p = 0.05).
|
30747249 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
In ALL, risk factors for relapse were disease status different from the first complete remission (CR1) at haplo-SCT (CR2 vs CR1: HR 2.85, p = 0.011; advanced vs CR1: HR 14.28, p < 0.0001) and male donor gender (HR 3.64, p = 0.0002), while in AML, risk factors were advanced disease at haplo-SCT (advanced vs CR1: HR 3.95, p < 0.0001) and comorbidities (HCT-CI) ≥ 3 (HR 1.75, p = 0.014).
|
31272508 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Increasingly accurate risk stratification in adults with AML CR1 aids the rational utilization of allo-SCT.
|
30585893 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Allo-SCT using MSD appears as a reasonable transplant option for young patients with iNPM1m AML in CR1.
|
30456896 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this paper, we review recent advances in allo-SCT for AML, weigh the benefits of allo-SCT for high-, intermediate-, and even low-risk AML in CR1, discuss the best choice of allo-SCT donor for the treatment of AML, and summarize new approaches for refractory and relapsed AML pre- or post-allo-SCT.
|
30926091 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results may serve as the background for randomized study comparing RIC versus MAC for haplo-SCT in adults with AML.
|
30620383 |
2019 |